SavedAdd your journal

Journals / Cukurova Medical Journal / 2022 / Cilt: 47 - Sayı: 3

Comparison of antiresorptive agents in the treatment of osteoporosis in older adults

Yaşlı yetişkinlerde osteoporoz tedavisinde antirezorptif ajanların karşılaştırılması

Eyyüp Murat EFENDİOĞLU
Ahmet ÇİĞİLOĞLU
Sencer GANİDAĞLI
Zeynel Abidin ÖZTÜRK
Pages
1248–1255
Publication Date
2022-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of our study may guide osteoporosis treatment in older individuals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: There are few studies comparing the effectiveness of anti-osteoporotic drugs among elderly population.
📊
Key Findings & Data:Materials and Methods: A total of 350 older adults with osteoporosis, aged 65 and over were included in this retrospective study.
💡
Conclusion & Impact:The results of our study may guide osteoporosis treatment in older individuals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Yaşlı yetişkinler · osteoporoz · alendronat

Abstract

Purpose: There are few studies comparing the effectiveness of anti-osteoporotic drugs among elderly population. In this study, we aimed to compare the effectiveness of alendronate, zoledronic acid, and denosumab in older adults. Materials and Methods: A total of 350 older adults with osteoporosis, aged 65 and over were included in this retrospective study. The number of patients receiving alendronate, zoledronic acid, and denosumab was 111, 121, and 118, respectively. Bone mineral density (BMD) was measured at baseline and 24th month by performing dual-energy x-ray absorptiometry (DXA) scans. Results: The age, comorbidities, and laboratory analysis results of the patients were similar. While there was no statistically significant difference in BMD response at the femoral neck between the treatment groups (Baseline BMDs for alendronate, zoledronic acid, and denosumab were 0.61, 0.59, and 0.58, respectively, while 24th month BMDs were 0.62, 0.60, and 0.59, respectively), alendronate and zoledronic acid improved lumbar spine BMD more than denosumab (Baseline BMDs for alendronate, zoledronic acid, and denosumab were 0.74, 0.74, and 0.71, respectively, while 24th month BMDs were 0.77, 0.78, and 0.73). Conclusion: This study has shown that, like parenteral antiresorptive agents, alendronate can elicit a desirable BMD response in older osteoporotic adults. The results of our study may guide osteoporosis treatment in older individuals.

Özet

Amaç: Yaşlı popülasyonda anti-osteoporotik ilaçların etkinliğini karşılaştıran az sayıda çalışma bulunmaktadır. Bu çalışmada yaşlı yetişkinlerde alendronat, zoledronik asit ve denosumabın etkinliğini karşılaştırmayı amaçladık. Gereç ve Yöntem: Bu retrospektif çalışmaya 65 yaş ve üzeri osteoporozlu toplam 350 yaşlı dahil edildi. Alendronat, zoledronik asit ve denosumab alan hasta sayısı sırasıyla 111, 121 ve 118 idi. Kemik mineral yoğunluğu (KMY) başlangıçta ve 24. ayda çift enerjili x-ışını absorpsiyometri (DXA) taramaları yapılarak ölçüldü. Bulgular: Hastaların yaşı, komorbiditeleri ve laboratuvar analiz sonuçları benzerdi. Tedavi grupları arasında femur boynunda KMY yanıtında istatistiksel olarak anlamlı bir fark bulunmazken (alendronat, zoledronik asit ve denosumab için başlangıç KMY'leri sırasıyla 0,61, 0,59 ve 0,58 iken 24. ay KMY'leri sırasıyla 0,62, 0,60 ve 0,59 idi), alendronat ve zoledronik asitin lomber omurga KMY'sini denosumab'dan daha fazla iyileştirdiğini bulduk (alendronat, zoledronik asit ve denosumab için başlangıç KMY'leri sırasıyla 0,74, 0,74 ve 0,71 iken, 24. ay KMY'leri sırasıyla 0,77, 0,78 ve 0,73 idi). Sonuç: Bu çalışma, parenteral antirezorptif ajanlar gibi, alendronatın da yaşlı osteoporotik yetişkinlerde istenilen KMY yanıtını ortaya çıkarabildiğini göstermiştir. Çalışmamızın sonuçları yaşlı bireylerde osteoporoz tedavisine rehberlik edebilir.

🔖

Cite This Article

EFENDİOĞLU, E. M., ÇİĞİLOĞLU, A., GANİDAĞLI, S., ÖZTÜRK, Z. A. (2022). Comparison of antiresorptive agents in the treatment of osteoporosis in older adults. Cukurova Medical Journal, Cilt: 47 - Sayı: 3, 1248–1255. https://ajindex.com/articles/482148

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81
  2. Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E et al. [Guidelines for the diagnosis, prevention and treatment of osteoporosis]. Reumatismo. 2009;61:260–84
  3. Kanis JA. Assessment of osteoporosis at the primary health-care level. Technical Report [Internet]. Available from: http//www. shef. ac. uk/FRAX, 2008
  4. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99
  5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22
  6. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401–19
  7. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513– 23
  8. Lin T, Wang C, Cai X-Z, Zhao X, Shi M-M, Ying Z- M et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta- analysis. Int J Clin Pract. 2012;66:399–408
  9. Pedersen AB, Heide-Jørgensen U, Sørensen HT, Prieto-Alhambra D, Ehrenstein V. Comparison of risk of osteoporotic fracture in denosumab vs alendronate treatment within 3 years of initiation. JAMA Netw Open. 2019;2:e192416
  10. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595–611
  11. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395-408
  12. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007 Aug;18(8):1033-46
  13. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ,